L6785
Lactacystin
≥90% (HPLC), powder, proteosome inhibitor
Se connecter pour consulter les tarifs organisationnels et contractuels.
Sélectionner une taille de conditionnement
Changer de vue
A propos de cet article
Formule empirique (notation de Hill) :
C15H24N2O7S
Numéro CAS:
Poids moléculaire :
376.43
UNSPSC Code:
12352200
PubChem Substance ID:
NACRES:
NA.77
MDL number:
Service technique
Besoin d'aide ? Notre équipe de scientifiques expérimentés est là pour vous.
Laissez-nous vous aiderNom du produit
Lactacystin, ≥90% (HPLC)
Quality Level
assay
≥90% (HPLC)
form
powder
potency
4 nM Ki (proteasome inhibitor)
solubility
water: 10 mg/mL, clear, colorless
storage temp.
−20°C
SMILES string
CC(C)[C@H](O)[C@]1(NC(=O)[C@H](C)[C@@H]1O)C(=O)SC[C@H](NC(C)=O)C(O)=O
InChI
1S/C15H24N2O7S/c1-6(2)10(19)15(11(20)7(3)12(21)17-15)14(24)25-5-9(13(22)23)16-8(4)18/h6-7,9-11,19-20H,5H2,1-4H3,(H,16,18)(H,17,21)(H,22,23)/t7-,9+,10+,11+,15-/m1/s1
InChI key
DAQAKHDKYAWHCG-RWTHQLGUSA-N
General description
Lactacystin is an antibiotic and a metabolite of Streptomyces spp.
Application
Lactacystin has been used:
- as a proteasome inhibitor to inhibit protein degradation
- to inhibit proteasomal activity of cells for live cell imaging
- to block proteasomal proteolysis in human monocyte-derived dendritic cells (MoDCs) for 24 h
- to provide unilateral injection to animals to induce nigrostriatal lesions
Biochem/physiol Actions
Lactacystin can block the development of cell cycle and stimulate differentiation in a murine neuroblastoma cell line. It can serve as a precursor for clasto-lactacystin β-lactone. Cell-permeable and irreversible proteasome inhibitor (Ki = 4nM). Inhibits NF-kB activation (IC50 = 10mM). Induces neurite outgrowth in neuro2A mouse neuroblastoma cells.
Classe de stockage
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
ppe
Eyeshields, Gloves, type N95 (US)
Faites votre choix parmi les versions les plus récentes :
Déjà en possession de ce produit ?
Retrouvez la documentation relative aux produits que vous avez récemment achetés dans la Bibliothèque de documents.
Contenu apparenté
Differential regulation of MHC II and invariant chain expression during maturation of monocyte-derived dendritic cells
Landsverk O J B, et al.
Journal of Leukocyte Biology, 91(5), 729-737 (2012)
Evolution of extra-nigral damage predicts behavioural deficits in a rat proteasome inhibitor model of Parkinson's disease
Vernon A C, et al.
PLoS ONE, 6(2), e17269-e17269 (2011)
Dallas S Shi et al.
The Journal of clinical investigation, 124(9), 3757-3766 (2014-07-26)
The proteasome inhibiter bortezomib has been successfully used to treat patients with relapsed multiple myeloma; however, many of these patients become thrombocytopenic, and it is not clear how the proteasome influences platelet production. Here we determined that pharmacologic inhibition of